Argenica Therapeutics Ltd News

Argenica Therapeutics Ltd: Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

Sep 6 06:55

Argenica Therapeutics Ltd: Appendix 4G & Corporate Governance Statement

Aug 28 15:18

Argenica Therapeutics Ltd: Appendix 4E & Annual Report to 30 June 2024

Aug 28 15:16

Argenica Therapeutics Ltd: Change of Director's Interest Notice

Aug 14 14:22

Argenica Therapeutics Ltd: Notification regarding unquoted securities - AGN

Aug 14 14:19

Argenica Therapeutics Ltd: Results of Meeting

Aug 14 09:43

Argenica Therapeutics Ltd: Change of Director's Interest Notice x3

Aug 8 06:28

Argenica Therapeutics Ltd: Cleansing Notice

Aug 8 06:28

Argenica Therapeutics Ltd: Notification of cessation of securities - AGN

Aug 8 06:28

Argenica Therapeutics Ltd: Application for quotation of securities - AGN

Aug 8 06:27

Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 31 08:29

Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update

Jul 24 06:16

Argenica Therapeutics Ltd: Investor Webinar Presentation

Jul 22 06:14

Argenica Therapeutics Ltd: Investor Presentation

Jul 15 06:27

Argenica Therapeutics Ltd: Notice of General Meeting/Proxy Form

Jul 12 06:23

Argenica Therapeutics Ltd: Notice of initial substantial holder from IFL

Jul 9 10:20

Argenica Therapeutics Ltd: Cleansing Notice

Jun 14 06:20

Argenica Therapeutics Ltd: Notification of cessation of securities - AGN

Jun 14 06:20

Argenica Therapeutics Ltd: Application for quotation of securities - AGN

Jun 14 06:19

Argenica Therapeutics Ltd: Notification of cessation of securities - AGN

Jun 12 15:20